COMMUNIQUÉS West-GlobeNewswire

VIVUS Announces Positive Outcome of European Procedure to Extend QSIVA® (Phentermine/Topiramate MR) to Adolescents with Obesity
19/10/2026
— Landmark European approval will grant young patients and families an evidence-based therapy alongside lifestyle interventions AMSTERDAM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a [...]
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
19/10/2026
ALISO VIEJO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and [...]
ProSomnus Announces Significant Scientific, Technical, and Advocacy Updates
19/10/2026
World-Renowned Sleep Medicine Leaders Join ProSomnus Medical Advisory Board, RPMO₂ Enhancements, Published FLOSAT Study Results, and Scientific Contributions at CHEST 2026 SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE [...]
Beacon Biosignals Partners with Project Sleep to Shorten the Path to Diagnosis for People with Idiopathic Hypersomnia and Narcolepsy
19/10/2026
The partnership connects Beacon's AI-driven neurotechnology with the patient-led advocacy community, expanding access to diagnosis and bringing patient voices directly into clinical research BOSTON, Oct. 19, 2026 (GLOBE [...]
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
19/10/2026
Premier sponsorship of the HERmedicine and OncoMenopause Consortium ® program underscores Daré Bioscience's commitment to addressing unmet women’s health needs, including for women affected by breast cancer The program [...]
OneMedNet Signs Global Pharmaceutical Intelligence Provider as Channel Partner, Extending Reach in Pharma Market
19/10/2026
Agreement with a leading global provider of pharmaceutical intelligence and data solutions expands distribution of OneMedNet’s first-party, direct-from-source multimodal Real-World Data; Strengthening its presence in a [...]
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
19/10/2026
TEL AVIV, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that it will shift its strategic focus toward Agentic AI-powered technologies, including [...]
Fangzhou and Cutia Therapeutics Partner to Advance AI-Powered Dermatology and Chronic Health Management
19/10/2026
GUANGZHOU, China, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, announced a strategic partnership with Cutia [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
19/10/2026
In advance of November 10, 2026 GDUFA goal date, three commercial lots of Preservative-Free Ketamine have been successfully manufactured in compliance with “Process Validation” required under FDA “Good Manufacturing [...]
ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules
19/10/2026
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI’s Duloxetine [...]
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
19/10/2026
Late-breaking oral presentation will feature first data from the global ROSETTA Lung-107 Phase 2 clinical trial evaluating pumitamig, a PD-L1×VEGF-A bispecific immunomodulator , plus docetaxel in patients with [...]
Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
19/10/2026
CALGARY, Alberta , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) , and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug [...]
Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany
19/10/2026
Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2 026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its [...]
Communiqué de presse : Sanofi pose la première pierre d’une nouvelle unité de production d’insuline de pointe en Allemagne
19/10/2026
Sanofi pose la première pierre d’une nouvelle unité de production d’insuline de pointe en Allemagne Paris et Francfort, le 19 octobre 2026. Sanofi a posé aujourd’hui la première pierre de sa nouvelle unité de production [...]
Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany
19/10/2026
Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2 026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its [...]
Communiqué de presse : Sanofi pose la première pierre d’une nouvelle unité de production d’insuline de pointe en Allemagne
19/10/2026
Sanofi pose la première pierre d’une nouvelle unité de production d’insuline de pointe en Allemagne Paris et Francfort, le 19 octobre 2026. Sanofi a posé aujourd’hui la première pierre de sa nouvelle unité de production [...]
Quanta Therapeutics Announces Presentation of QTX3034 Clinical Combination Data with Anti-EGFR and Chemotherapy in Colorectal Cancer (CRC) at ESMO and Fast Track Designation for Patients with KRAS G12D Mutations
19/10/2026
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately held, clinical-stage biopharmaceutical company leading the development of innovative therapeutics for RAS- [...]
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
19/10/2026
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
TLC590 Achieves Statistically Significant Reductions in Pain and Opioid Use Versus Both Placebo and Liposomal Bupivacaine in Pivotal Phase 3 Trial
19/10/2026
Met Primary Endpoint: Significant pain reduction through 72 hours vs. placebo. Significantly Reduced Opioid Use: Outperformed both placebo and liposomal bupivacaine head-to-head in pain reduction and opioid consumption [...]

Pages